Chardan Capital Maintains Buy on Purple Biotech, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Daniil Gataulin maintains a Buy rating on Purple Biotech (NASDAQ:PPBT) with an $11 price target.
March 07, 2024 | 6:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Daniil Gataulin reaffirms a Buy rating on Purple Biotech with an $11 price target.
The reaffirmation of a Buy rating and an $11 price target by a Chardan Capital analyst is a strong positive signal for Purple Biotech. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100